The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

In a report released today, Jo Walton from UBS maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

One of the researchers described the circumstances that led to the discovery as “serendipity.” This year’s prestigious Lasker ...

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care ...

It’s a brain disease,” a prominent obesity doctor explained on a “60 Minutes” episode about the drugs. “Obesity is disease” ...

Senator Sanders (I-Vt.) says CEOs of generic drugmakers are willing to sell Novo Nordisk’s (NVO) blockbuster obesity medicine ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.